Loading...
NPI 1609826304 · Pittsburgh, PA · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Interpace Diagnostics Corporation is a clinical medical laboratory provider located in Pittsburgh, Pennsylvania. This profile covers 6 Medicare and 9 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Interpace Diagnostics Corporation |
| Address | 2515 Liberty Ave |
| City | Pittsburgh |
| State | PA |
| ZIP | 15222 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | May 11, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $15.5M |
| Medicaid | $576.6K |
INTERPACE DIAGNOSTICS appears to operate as a specialized molecular pathology laboratory focused on thyroid diagnostic assays: its top Medicare revenue drivers are PLA and molecular pathology codes (0018U, 0245U, and 81479) that describe ThyraMIR, ThyGeNEXT®, and a catch-all molecular pathology code respectively. The code mix—high revenue per claim for PLA codes and meaningful volume on 81479—is consistent with a business that markets proprietary genomic/algorithmic thyroid tests to clinicians performing fine needle aspiration evaluation.
Revenue concentration on Medicare is extremely high and narrowly focused: the top 3 Medicare codes by revenue account for 99.4% of this provider's total Medicare revenue, with 81479 generating $8.6M (55.6% of Medicare revenue), 0018U generating $4.6M (29.8%), and 0245U generating $2.2M (14.0%). This concentration signals that Medicare earnings are dominated by a small set of specialized diagnostic assays rather than a broad panel of routine lab testing.
Medicaid revenue is also concentrated in the same thyroid-focused assays: the top 3 Medicaid codes by revenue account for 87.5% of this provider's total Medicaid revenue, led by 0018U at $272.4K (47.0%), 81479 at $175.6K (30.3%), and 0245U at $58.7K (10.1%). The Medicaid mix mirrors Medicare’s product focus but at a much smaller absolute scale, indicating the lab’s commercial strategy is consistent across payers but Medicaid contributes only a fraction of total revenue.
Payer mix is heavily Medicare-dominant in scale: lifetime Medicare revenue is $15.5M versus lifetime Medicaid revenue of $576.6K, so this provider’s billed activity and revenue generation are concentrated in Medicare. While both payers show the same specialty assays in their top codes, Medicare represents the overwhelming share of this entity’s public-payer business.
Competitively, Interpace is a national leader for its proprietary PLA thyroid tests: 0018U ranks #1 of 2 providers nationally (100th percentile; typical, unremarkable volume for this code) and 0245U ranks #1 of 2 providers nationally (100th percentile; typical, unremarkable volume for this code), indicating the company is one of the very small number of labs billing those PLA identifiers at scale. For the broader molecular pathology code 81479 it ranks #11 of 80 providers nationally (87th percentile; typical, unremarkable volume for this code), which positions the provider as a meaningful but not dominant user of the non-proprietary molecular pathology code.
Several lower-revenue, routine chemistry and cytology codes appear as ancillary services rather than revenue drivers: codes like 82150 ($2.6K Medicare revenue; ranks #130 of 1236 nationally, 89th percentile) and 82945 ($972 Medicare revenue; ranks #21 of 96 nationally, 79th percentile) account for negligible Medicare revenue but show the lab also performs or bills some routine assays. In Medicaid these routine codes likewise contribute little dollar volume (for example 82150 $3.6K and 82945 $555) but their relatively high percentile ranks in state peer comparisons suggest the lab’s routine testing volume is unremarkable to moderately elevated within its peer set.
Several state-level rankings indicate limited in-state peer comparisons for the PLA tests: in the Medicaid dataset 0018U and 0245U both rank #1 of 1 providers in-state with a notation of "0th percentile; no state peer volume comparison available," which reflects that Interpace may be the sole or principal in-state biller of these proprietary codes rather than a large local competitive field. That lack of in-state peer volume makes state-level competitive benchmarking for those PLAs less informative than the national ranking.
The provider has a long tenure on file, with NPI enumerated 2006-05-11 (~20 years ago), which aligns with the establishment of a stable specialty lab business and the ability to develop proprietary assays over time. Combined with the concentrated revenue mix and national leadership on PLA codes, the tenure supports an interpretation of a matured specialty diagnostic operation rather than a new entrant or a generalist clinical lab.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
6 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 81479 | Use 81479 to report a molecular pathology procedure that does not have a specific code. | 2,830 | $3,040 | $8.6M |
| 0018U | This is a Proprietary Laboratory Analyses (PLA) code, meaning that the code describes only one unique lab test made by a specific manufacturer or performed by a specific lab. Code 0018U describes… | 1,570 | $2,930 | $4.6M |
| 0245U | This is a Proprietary Laboratory Analyses (PLA) code, meaning that the code describes only one unique lab test made by a specific manufacturer or performed by a specific lab. Code 0245U describes… | 1,750 | $1,240 | $2.2M |
| 88381 | A clinician, typically a pathologist, performs a manual microdissection of a patient’s specimen, such as a biopsy or tissue preserved from a previous case. | 630 | $150 | $91.9K |
| 82150 | The lab analyst performs a quantitative measurement of amylase, typically in serum or urine. Amylase is primarily produced in the pancreas, but is also produced in the salivary gland. | 430 | $10 | $2.6K |
| 82945 | The lab analyst measures the glucose in any of a variety of specimen types, such as in spinal fluid, urine, joint fluid, and from other locations such as fluid from the abdomen or the lung cavity. | 240 | $1 | $970 |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 6 CPT/HCPCS codes.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
9 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 0018U | This is a Proprietary Laboratory Analyses (PLA) code, meaning that the code describes only one unique lab test made by a specific manufacturer or performed by a specific lab. Code 0018U describes… | 1,920 | $140 | $272.4K |
| 81479 | Use 81479 to report a molecular pathology procedure that does not have a specific code. | 1,430 | $120 | $175.6K |
| 0245U | This is a Proprietary Laboratory Analyses (PLA) code, meaning that the code describes only one unique lab test made by a specific manufacturer or performed by a specific lab. Code 0245U describes… | 920 | $60 | $58.7K |
| 81445 | The lab analyst performs a genomic sequence analysis panel to evaluate the patient tumor specimen for DNA and possibly RNA alterations in five to 50 genes known to impact solid organ cancers. | 1,250 | $40 | $50.1K |
| 82378 | The lab analyst performs the technical lab test to analyze the quantity of carcinoembryonic antigen, or CEA, in the blood or other bodily fluid. Most commonly clinicians order a CEA test to monitor… | 1,890 | $10 | $9.5K |
| 88381 | A clinician, typically a pathologist, performs a manual microdissection of a patient’s specimen, such as a biopsy or tissue preserved from a previous case. | 420 | $20 | $7.1K |
| 82150 | The lab analyst performs a quantitative measurement of amylase, typically in serum or urine. Amylase is primarily produced in the pancreas, but is also produced in the salivary gland. | 1,780 | $1 | $3.6K |
| 88173 | The lab analyst performs the technical lab test to analyze a cytopathology specimen from a fine needle aspirate and then interprets and reports the results. | 70 | $30 | $1.8K |
| 82945 | The lab analyst measures the glucose in any of a variety of specimen types, such as in spinal fluid, urine, joint fluid, and from other locations such as fluid from the abdomen or the lung cavity. | 560 | $1 | $560 |
How this provider's Medicaid billing volume and revenue compare to other Pennsylvania providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Pennsylvania median
9 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 0018U | This is a Proprietary Laboratory Analyses (PLA) code, meaning that the code describes only one unique lab test made by a specific manufacturer or performed by a specific lab. Code 0018U describes… | 1 | 10 | 1,920 | $140 | $271.5K |
| 81479 | Use 81479 to report a molecular pathology procedure that does not have a specific code. | 2 | 10 | 280 | $1 | $74.6K |
| 0245U | This is a Proprietary Laboratory Analyses (PLA) code, meaning that the code describes only one unique lab test made by a specific manufacturer or performed by a specific lab. Code 0245U describes… | 1 | 10 | 920 | $60 | $58.3K |
| 81445 | The lab analyst performs a genomic sequence analysis panel to evaluate the patient tumor specimen for DNA and possibly RNA alterations in five to 50 genes known to impact solid organ cancers. | 1 | 10 | 1,250 | $40 | $50K |
| 88173 | The lab analyst performs the technical lab test to analyze a cytopathology specimen from a fine needle aspirate and then interprets and reports the results. | 10 | 20 | 70 | $50 | $7.6K |
| 88381 | A clinician, typically a pathologist, performs a manual microdissection of a patient’s specimen, such as a biopsy or tissue preserved from a previous case. | 1 | 10 | 420 | $20 | $7.1K |
| 82378 | The lab analyst performs the technical lab test to analyze the quantity of carcinoembryonic antigen, or CEA, in the blood or other bodily fluid. Most commonly clinicians order a CEA test to monitor… | 3 | 40 | 120 | $10 | $4K |
| 82150 | The lab analyst performs a quantitative measurement of amylase, typically in serum or urine. Amylase is primarily produced in the pancreas, but is also produced in the salivary gland. | 8 | 90 | 220 | $1 | $2.4K |
| 82945 | The lab analyst measures the glucose in any of a variety of specimen types, such as in spinal fluid, urine, joint fluid, and from other locations such as fluid from the abdomen or the lung cavity. | 1 | 10 | 130 | $1 | $570 |
Other providers in the same ZIP code as Interpace Diagnostics Corporation, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Benjamin Harris | PA | Diagnostic Radiology Physician | $527.8K | $504.9K |
| Todd Blodgett | PA | Diagnostic Radiology Physician | $380.1K | $254K |
| David Hursh | PA | Diagnostic Radiology Physician | $179K | $31.6K |
| Derek Armfield | PA | Diagnostic Radiology Physician | $125.1K | $67.3K |
| Ami Sethi | PA | Diagnostic Radiology Physician | $169.1K | $7.6K |
| Susanj Patel | PA | Diagnostic Radiology Physician | $167.7K | $5.9K |
| Stephen Kelminson | PA | Vascular & Interventional Radiology Physician | $141.1K | $740 |
| Ramesh Tank | PA | Diagnostic Radiology Physician | $109.6K | $2.6K |
| Veeral Bhoot | PA | Vascular & Interventional Radiology Physician | $92.3K | $18K |
| Neda Rastegar | PA | Diagnostic Radiology Physician | $99.7K | $4.1K |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.